Renaissance Technologies LLC Has $15.12 Million Stock Holdings in LeMaitre Vascular, Inc. $LMAT

Renaissance Technologies LLC lowered its position in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 23.3% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 138,502 shares of the medical instruments supplier’s stock after selling 42,000 shares during the period. Renaissance Technologies LLC’s holdings in LeMaitre Vascular were worth $15,120,000 as of its most recent SEC filing.

A number of other hedge funds have also recently added to or reduced their stakes in LMAT. Sound Income Strategies LLC lifted its holdings in shares of LeMaitre Vascular by 425.6% in the 1st quarter. Sound Income Strategies LLC now owns 226 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 183 shares in the last quarter. Catalyst Capital Advisors LLC bought a new stake in LeMaitre Vascular during the 1st quarter valued at $32,000. Geneos Wealth Management Inc. raised its holdings in LeMaitre Vascular by 250.3% during the first quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after buying an additional 398 shares during the last quarter. EverSource Wealth Advisors LLC bought a new position in shares of LeMaitre Vascular in the second quarter valued at $47,000. Finally, Quarry LP lifted its stake in shares of LeMaitre Vascular by 267.2% in the third quarter. Quarry LP now owns 727 shares of the medical instruments supplier’s stock valued at $64,000 after buying an additional 529 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Insider Transactions at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 27,881 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $108.69, for a total value of $3,030,385.89. Following the transaction, the chief executive officer owned 1,430,019 shares in the company, valued at $155,428,765.11. The trade was a 1.91% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Trent G. Kamke sold 2,928 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $107.00, for a total value of $313,296.00. Following the sale, the insider directly owned 3,749 shares of the company’s stock, valued at $401,143. The trade was a 43.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 54,453 shares of company stock worth $5,906,174 in the last 90 days. Insiders own 7.40% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday. Citigroup reaffirmed a “market outperform” rating on shares of LeMaitre Vascular in a research report on Tuesday, July 21st. Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Weiss Ratings downgraded LeMaitre Vascular from a “buy (b)” rating to a “buy (b-)” rating in a research note on Tuesday, June 30th. Finally, Wells Fargo & Company raised their target price on LeMaitre Vascular from $94.00 to $104.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. Five analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $112.60.

LeMaitre Vascular Stock Performance

Shares of LMAT stock opened at $101.32 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 14.32 and a quick ratio of 12.20. The firm has a 50-day moving average of $97.15 and a 200-day moving average of $99.65. LeMaitre Vascular, Inc. has a one year low of $79.00 and a one year high of $118.01. The company has a market cap of $2.32 billion, a P/E ratio of 37.39, a P/E/G ratio of 2.84 and a beta of 0.52.

LeMaitre Vascular (NASDAQ:LMAT) last issued its quarterly earnings data on Tuesday, May 5th. The medical instruments supplier reported $0.68 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.66 by $0.02. The business had revenue of $66.55 million during the quarter, compared to the consensus estimate of $66.67 million. LeMaitre Vascular had a net margin of 24.35% and a return on equity of 15.36%. The firm’s quarterly revenue was up 11.1% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.48 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.930-3.080 EPS and its Q2 2026 guidance at 0.790-0.840 EPS. Equities research analysts forecast that LeMaitre Vascular, Inc. will post 3 EPS for the current fiscal year.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.